IHC showed that the mice treated with cisplatin plus eIF5A2 silencing had the lowest Ki67 levels (Fig. 6E) and the highest terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) staining (Fig. 6F), indicating that the combined treatment effectively reversed hypoxia-induced autophagy and inhibited NSCLC development (Fig. 6D, F and Fig. S2). The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.